Cancer Research Versailles No Abst Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chakravarti, A.
Right arrow Articles by Loeffler, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chakravarti, A.
Right arrow Articles by Loeffler, J. S.
[Cancer Research 62, 4307-4315, August 1, 2002]
© 2002 American Association for Cancer Research

Experimental Therapeutics

The Epidermal Growth Factor Receptor Pathway Mediates Resistance to Sequential Administration of Radiation and Chemotherapy in Primary Human Glioblastoma Cells in a RAS-dependent Manner1

Arnab Chakravarti2, Abhijit Chakladar, Meaghan A. Delaney, Douglas E. Latham and Jay S. Loeffler

Department of Radiation Oncology, Massachusetts General Hospital/Harvard Medical School, Charlestown, Massachusetts 02129 [A. C., M. A. D., D. E. L., J. S. L.] and Department of Medicine, University of Massachusetts School of Medicine [A. C.], Worcester, Massachusetts 01655

Resistance to conventional adjuvant therapies (i.e., chemotherapy and radiation) has been welldocumented in malignant gliomas. Unlike many other tumor types, combined modality therapy involving radiation and chemotherapy has failed to appreciably enhance outcome for glioblastoma patients compared with radiation alone. In vitro, we have observed an actual antagonistic effect between sequential administration of radiation and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) chemotherapy in three primary human glioblastoma cell lines (referred as the GBME3-5 cell lines), which also happen to demonstrate strong expression of the epidermal growth factor receptor (EGFR). Upon inhibition of EGFR with the EGFR tyrosine kinase inhibitor, AG1478, it was found that this cross-resistance between sequential administration of radiation and BCNU was abrogated. To dissect which of these pathways may be responsible for the observed antagonism, known EGFR-regulated downstream signaling pathways including RAS, phosphatidylinositol 3-kinase (PI3-K), mitogen-activated protein kinase (p44/p42), and protein kinase C were inactivated with both pharmacological inhibitors and transient transfection experiments with dominant-negative and constitutively active constructs in the presence of exogenous EGF stimulation. It was found that BCNU inhibited radiation-induced apoptosis through EGFR-mediated activation of PI3-K/AKT via RAS. On the other hand, radiation was found to inhibit BCNU-induced apoptosis through EGFR-mediated activation of both PI3-K and mitogen-activated protein kinase (p44/p42) pathways, also via RAS. Inhibition of either EGFR or RAS activity appears to not only abrogate the observed antagonism between sequentially administered radiation and chemotherapy but actually results in a greater enhancement of apoptosis in the setting of combined modality therapy than when administered with either radiation or chemotherapy as single agents. Therefore, these findings suggest that strategies to inactivate EGFR or RAS signaling may be critical to improving not only the efficacy of single-agent therapy but also of combined modality therapy in gliomas.




This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
T. Okamura, S. Singh, J. Buolamwini, T. Haystead, H. Friedman, D. Bigner, and F. Ali-Osman
Tyrosine Phosphorylation of the Human Glutathione S-Transferase P1 by Epidermal Growth Factor Receptor
J. Biol. Chem., June 19, 2009; 284(25): 16979 - 16989.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J.-S. Guillamo, S. de Bouard, S. Valable, L. Marteau, P. Leuraud, Y. Marie, M.-F. Poupon, J.-J. Parienti, E. Raymond, and M. Peschanski
Molecular Mechanisms Underlying Effects of Epidermal Growth Factor Receptor Inhibition on Invasion, Proliferation, and Angiogenesis in Experimental Glioma
Clin. Cancer Res., June 1, 2009; 15(11): 3697 - 3704.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Broniscer, S. J. Baker, C. F. Stewart, T. E. Merchant, F. H. Laningham, P. Schaiquevich, M. Kocak, E. B. Morris, R. Endersby, D. W. Ellison, et al.
Phase I and Pharmacokinetic Studies of Erlotinib Administered Concurrently with Radiotherapy for Children, Adolescents, and Young Adults with High-Grade Glioma
Clin. Cancer Res., January 15, 2009; 15(2): 701 - 707.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. E. Eyler and J. N. Rich
Survival of the Fittest: Cancer Stem Cells in Therapeutic Resistance and Angiogenesis
J. Clin. Oncol., June 10, 2008; 26(17): 2839 - 2845.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. C. Manegold, C. Paringer, U. Kulka, K. Krimmel, M. E. Eichhorn, R. Wilkowski, K.-W. Jauch, M. Guba, and C. J. Bruns
Antiangiogenic Therapy with Mammalian Target of Rapamycin Inhibitor RAD001 (Everolimus) Increases Radiosensitivity in Solid Cancer
Clin. Cancer Res., February 1, 2008; 14(3): 892 - 900.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
D. A. Reardon, A. Desjardins, J. J. Vredenburgh, S. Sathornsumetee, J. N. Rich, J. A. Quinn, T. F. Lagattuta, M. J. Egorin, S. Gururangan, R. McLendon, et al.
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: Phase 1 trial in adults with malignant glioma
Neuro-oncol, January 1, 2008; 10(3): 330 - 340.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
F. B. Furnari, T. Fenton, R. M. Bachoo, A. Mukasa, J. M. Stommel, A. Stegh, W. C. Hahn, K. L. Ligon, D. N. Louis, C. Brennan, et al.
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Genes & Dev., November 1, 2007; 21(21): 2683 - 2710.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. N. Rich
Cancer Stem Cells in Radiation Resistance
Cancer Res., October 1, 2007; 67(19): 8980 - 8984.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. E. Pelloski, K. V. Ballman, A. F. Furth, L. Zhang, E. Lin, E. P. Sulman, K. Bhat, J. M. McDonald, W.K. A. Yung, H. Colman, et al.
Epidermal Growth Factor Receptor Variant III Status Defines Clinically Distinct Subtypes of Glioblastoma
J. Clin. Oncol., June 1, 2007; 25(16): 2288 - 2294.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Zhou, R. Miki, M. Eeva, F. M. Fike, D. Seligson, L. Yang, A. Yoshimura, M. A. Teitell, C. A.M. Jamieson, and N. A. Cacalano
Reciprocal Regulation of SOCS 1 and SOCS3 Enhances Resistance to Ionizing Radiation in Glioblastoma Multiforme
Clin. Cancer Res., April 15, 2007; 13(8): 2344 - 2353.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. C. Manara, L. Landuzzi, P. Nanni, G. Nicoletti, D. Zambelli, P. L. Lollini, C. Nanni, F. Hofmann, C. Garcia-Echeverria, P. Picci, et al.
Preclinical In vivo Study of New Insulin-Like Growth Factor-I Receptor-Specific Inhibitor in Ewing's Sarcoma
Clin. Cancer Res., February 15, 2007; 13(4): 1322 - 1330.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Chakravarti, M. G. Erkkinen, U. Nestler, R. Stupp, M. Mehta, K. Aldape, M. R. Gilbert, P. McL. Black, and J. S. Loeffler
Temozolomide-Mediated Radiation Enhancement in Glioblastoma: A Report on Underlying Mechanisms
Clin. Cancer Res., August 1, 2006; 12(15): 4738 - 4746.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. N. Sarkaria, B. L. Carlson, M. A. Schroeder, P. Grogan, P. D. Brown, C. Giannini, K. V. Ballman, G. J. Kitange, A. Guha, A. Pandita, et al.
Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response.
Clin. Cancer Res., April 1, 2006; 12(7 Pt 1): 2264 - 2271.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. A. Reardon, J. N. Rich, H. S. Friedman, and D. D. Bigner
Recent Advances in the Treatment of Malignant Astrocytoma
J. Clin. Oncol., March 10, 2006; 24(8): 1253 - 1265.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. A. Reardon, M. J. Egorin, J. A. Quinn, J. N. Rich Sr, I. Gururangan, J. J. Vredenburgh, A. Desjardins, S. Sathornsumetee, J. M. Provenzale, J. E. Herndon II, et al.
Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme
J. Clin. Oncol., December 20, 2005; 23(36): 9359 - 9368.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. Kassouf, C. P.N. Dinney, G. Brown, D. J. McConkey, A. J. Diehl, M. Bar-Eli, and L. Adam
Uncoupling between Epidermal Growth Factor Receptor and Downstream Signals Defines Resistance to the Antiproliferative Effect of Gefitinib in Bladder Cancer Cells
Cancer Res., November 15, 2005; 65(22): 10524 - 10535.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I.-A. Kim, S.-S. Bae, A. Fernandes, J. Wu, R. J. Muschel, W. G. McKenna, M. J. Birnbaum, and E. J. Bernhard
Selective Inhibition of Ras, Phosphoinositide 3 Kinase, and Akt Isoforms Increases the Radiosensitivity of Human Carcinoma Cell Lines
Cancer Res., September 1, 2005; 65(17): 7902 - 7910.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Chakravarti, G. Zhai, Y. Suzuki, S. Sarkesh, P. M. Black, A. Muzikansky, and J. S. Loeffler
The Prognostic Significance of Phosphatidylinositol 3-Kinase Pathway Activation in Human Gliomas
J. Clin. Oncol., May 15, 2004; 22(10): 1926 - 1933.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Yokoi and I. J. Fidler
Hypoxia Increases Resistance of Human Pancreatic Cancer Cells to Apoptosis Induced by Gemcitabine
Clin. Cancer Res., April 1, 2004; 10(7): 2299 - 2306.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. M. Harari and S.-M. Huang
Searching for Reliable Epidermal Growth Factor Receptor Response Predictors: Commentary re M. K. Nyati et al., Radiosensitization by Pan-ErbB Inhibitor CI-1033 in Vitro and in Vivo. Clin. Cancer Res., 10: 691-700, 2004.
Clin. Cancer Res., January 15, 2004; 10(2): 428 - 432.
[Full Text] [PDF]

Home page
 Vet PatholHome page
G. Stoica, H.-T. Kim, D. G. Hall, and J. R. Coates
Morphology, Immunohistochemistry, and Genetic Alterations in Dog Astrocytomas
Vet. Pathol., January 1, 2004; 41(1): 10 - 19.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Shinojima, K. Tada, S. Shiraishi, T. Kamiryo, M. Kochi, H. Nakamura, K. Makino, H. Saya, H. Hirano, J.-i. Kuratsu, et al.
Prognostic Value of Epidermal Growth Factor Receptor in Patients with Glioblastoma Multiforme
Cancer Res., October 15, 2003; 63(20): 6962 - 6970.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. J. Gilbertson, D. A. Hill, R. Hernan, M. Kocak, R. Geyer, J. Olson, A. Gajjar, L. Rush, R. L. Hamilton, S. D. Finkelstein, et al.
ERBB1 Is Amplified and Overexpressed in High-grade Diffusely Infiltrative Pediatric Brain Stem Glioma
Clin. Cancer Res., September 1, 2003; 9(10): 3620 - 3624.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.